drugset / Trial / NCT01073605

Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation

NCT01073605

Phase 3 Completed 208 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation

Timeline

Start
1993-07
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Somatropin Protein / enzyme biologic 0.03 mg/kg Subcutaneous
Comparator Somatropin Protein / enzyme biologic 0.06 mg/kg Subcutaneous
Comparator Somatropin Protein / enzyme biologic 0.7 iu/kg Subcutaneous
Comparator Somatropin Protein / enzyme biologic 1.4 iu/kg Subcutaneous